Company* |
Company* |
Type/Product Area |
Terms/Details (Date) |
| | |||
4SC AG* |
Esteve SA* |
Collaboration to identify drug candidates directed at targets related to central nervous system diseases |
The collaboration is the extension of a pilot project in which 4SC identified hits against a target provided by Esteve (7/15) |
|
|
|
|
Agilent Technologies |
Dharmacon |
Collaboration to use Agilent's microarray and Dharmacon's RNA interference technologies to measure the broader cellular effects of RNAi, or gene silencing |
Dharmacon will silence the genes and apply Agilent's microarray solutions to measure the systemic effects; Agilent will analyze the data using the Rosetta Resolver gene expression data analysis system from Rosetta Biosoftware to assess effects on gene expression (6/24) |
|
|
||
Amersham Biosciences |
Geneva Bioinformatics |
Exclusive agreement to develop a 2-D gel image analysis tool for proteomics research |
The collaboration will integrate the Melanie 2-D Gel Analysis Software developed by the Swiss Institute of Bioinformatics into the ImageMaster image analysis software platform from Amersham (7/16) |
|
|
|
|
ArQule Inc. |
Inpharmatica |
Agreement for Inpharmatica to acquire certain ArQule assets, to take assignment of its Cambridge laboratories and to license certain intellectual property |
Fifteen former ArQule employees will join Inpharmatica following the deal (6/23) |
|
|
|
|
Array |
GenPath Pharmaceuticals Inc.* |
Drug discovery collaboration to identify small-molecule drugs that target a tumor maintenance gene discovered in GenPath's genetic model systems |
Array will receive research funding and be entitled to receive milestone payments based on the selection and progression of a development candidate (7/8) |
|
|
|
|
Beiersdorf |
Senetek |
Collaboration under which Beiersdorf will undertake laboratory and in vivo evaluations of various compounds to which Senetek has rights of use that may be licensed by Beiersdorf |
Beiersdorf may enter into license agreements for the use of the compound in specific markets worldwide; Senetek will own and have the right to practice and license all compounds resulting from the collaboration outside the markets and fields (6/25) |
|
|
|
|
Biolex Inc.* |
Centocor |
Research collaboration to examine the feasibility of producing three proteins using Biolex's Lemna Expression System |
Biolex will be responsible for the expression of Centocor's three therapeutic proteins (6/23) |
|
|||
BioSeek |
Dynavax Technologies |
Collaboration to apply its BioMAP human cell-based model systems technology to analyze and characterize the activity of thiazolopyrimidine compounds with Dynavax |
BioSeek will receive milestone payments and royalties on sales of resulting products, which Dynavax is developing for chronic inflammatory diseases (6/24) |
|
|
||
Braintree Laboratories Inc.* |
Nabi Biopharmaceuticals Inc. (NABI) |
Agreement for a product to treat patients with endstage renal failure |
Nabi paid Braintree $100M to acquire PhosLo, which is used to treat end-stage renal disease; Braintree will continue to manufacture the product for Nabi under a long-term agreement (8/5) |
|
|||
Caliper Technologies Corp. (CALP) |
Serono SA (Switzerland; NYSE:SRA) |
Agreement in which Serono bought the Caliper 250 drug discovery system to develop kinase assays |
Financial terms were not disclosed (7/21) |
|
|
||
Cengent Therapeutics Inc.* |
AGY |
Agreement for Cengent to provide X-ray crystallography services to AGY |
Cengent will supply its crystallography services to a target provided by AGY; the deal includes an up-front payment and potential milestone payments for Cengent (6/30) |
|
|
||
Chiron Corp. (CHIR) |
Gilead Sciences |
Nonexclusive licensing agreement related to small-molecule therapeutics against certain hepatitis C virus drug targets from Chiron |
Gilead gained the license; financial terms were not disclosed (8/4) |
|
|
|
|
Ciphergen Biosystems Inc. (CIPH) |
bioMerieux SA* (France) |
Agreement for Ciphergen to provide its ProteinChip Technology to bioMerieux |
The companies will jointly discover biomarkers and multibiomarker panels for colon cancer (6/30) |
|
|
||
Compugen |
Biocceleration |
Agreement in which |
Compugen will receive certain fixed payments during the next two years and royalties from future sales of the product line and any future products based on the Bioccelerator intellectual property (7/17) |
|
|
|
|
Connex GmbH* (Germany) and INSERM |
Genmab A/S (Denmark; |
Licensing agreement giving Genmab rights to a human antibody from Connex and INSERM |
The antibody targets the E2 envelope glycoprotein on the hepatitis C virus and is designed for use in preventing and treating infection; Genmab made a $1M up-front payment and will make milestone payments and royalties on eventual sales; it will be responsible for all further research and development (7/14) |
|
|
||
Corautus Genetics Inc. (AMEX:CAQ) |
Boston Scientific Corp. (NYSE:BSX) |
Agreement to develop and commercialize a gene therapy technology to treat cardiovascular disease, focusing initially on severe ischemic heart disease patients who have been unresponsive to conventional therapies |
Corautus is gaining $25M with the collaboration; Boston Scientific paid a $1M license fee for certain intellectual property, made a $9M investment in exchange for 10% of Corautus' equity on a fully diluted basis, and committed to purchasing up to $15M of convertible debt from Corautus based on achievement of certain milestones (7/30) |
|
|
|
|
Critical Therapeutics Inc.* |
MedImmune Inc. (MEDI) |
Agreement to co-develop drugs targeting a pro-inflammatory cytokine to treat severe inflammatory diseases |
MedImmune will pay Critical Therapeutics $12.5M in up-front fees (7/31) |
|
|
|
|
Crucell NV (the Netherlands; CRXL) |
GeneMax Corp. (OTC BB:GMXX) |
Agreement for Crucell to license its PER.C6 cell line technology to GeneMax |
GeneMax will use the technology for research in the field of adenovirus-based gene delivery, and it obtained an option or a nonexclusive commercial license to use PER.C6 cells to manufacture and sell gene delivery products; Crucell will receive up-front and annual payments for the research license, and if it is converted into a commercial license, Crucell would receive additional annual payments and royalties on future sales (8/12) |
|
|
|
|
CytoGenix |
BioZone Laboratories Inc.* |
Agreement to investigate the synergy of the companies' technologies in order to develop new formulations for select therapeutic categories |
The companies will use BioZone's liposome technology, QuSomes, to microscopically encapsulate CytoGenix's ssDNA expres- sion system sequences and protect them from metabolic destruction by exo- and endo-nucleases found on the skin and in the bloodstream (8/6) |
|
|
|
|
Dyax Corp. (DYAX) |
Affimed Therapeutics AG* (Germany) |
Cross-licensing agreement for phage display technologies |
Affimed's licensed patents cover the generation of human antibody libraries derived from the IgM repertoire of the immune system; Dyax's Ladner patents have the earliest priority date for phage display patents in the U.S. (8/12) |
|
|
||
Dyax Corp. (DYAX) |
Genzyme Corp. (GENZ) |
Agreement centered on the anti-inflammatory product |
Companies will split development costs for DX-88 in hereditary angioedema; Dyax will receive a milestone of $3M upon dosing of the first patient in a Phase II trial; it will receive $10M if DX-88 is approved for HAE, and another $15M if it's approved for a different chronic inflammatory indication (6/24) |
|
|
||
EpiCept |
Adolor |
Agreement in which Adolor obtained exclusive rights to develop and commercialize in North America a sterile topical lidocaine patch from EpiCept for postoperative incisional pain |
EpiCept received a $2.5M signing fee and is eligible to receive up to $20M in development milestone payments, as well as royalties (7/24) |
|
|
|
|
Evotec OAI |
Axxim Pharmaceuticals AG* (Germany) |
Medicinal chemistry agreement |
Evotec will apply its integrated medicinal chemistry platform to optimize initial screening hits already identified by Axxima and progress them toward candidates for clinical trials (6/25) |
|
|||
Gamete Technology |
ViaCell Inc.* |
Worldwide exclusive license for use of patented technology to cryopreserve unfertilized human oocytes |
ViaCell will control the patent rights and clinical applications of Gamete oocyte cryopreservation technology for use in in vitro fertilization clinics around the world; Gamete retains rights for applications related to other human cells and all veterinary applications (8/13) |
|
|
||
Gene Logic |
Five Prime Therapeutics |
Agreement in which Five Prime gained access to a BioExpress Custom Suite to use with its Pharmanome-based therapeutics discovery efforts |
Financial details of the multiyear subscription agreement were not disclosed (7/7) |
|
|
|
|
Genicon |
Invitrogen |
Agreement in which Invitrogen bought product lines and technology rights, including tools and methods for ultra-sensitive signal generation and detection from Genicon |
Invitrogen paid $2M for the rights (7/8) |
|
|
|
|
Genmab A/S (Denmark; CSE:GEN) |
Amgen |
Agreement in which Amgen exercised its option to license Genmab's HuMax-IL15 |
Genmab will receive a $10M milestone payment, plus the potential of up to $135.5M in license fees and other milestones; the deal also covers Genmab's interleukin-15 receptor program and a new antibody program for another disease target (7/1) |
|
|
||
GTC Biotherapeutics Inc. (GTCB) |
BioProtein Technologies* (France) |
Licensing agreement granting BioProtein certain rights to |
The rights cover all European Union countries, plus Switzerland and Turkey (6/18**) |
|
|
||
Guava Technologies Inc.* |
Partners HealthCare* |
Clinical research alliance in |
Guava's personal cell analysis systems, the Guava PCA and Guava PCA-96, are designed to simplify cell analysis and biological research (8/7) |
|
|
|
|
Human Genome Sciences Inc. (HGSI) |
Genentech Inc. (NYSE:DNA) |
License agreement under which Genentech acquired exclusive, worldwide patent rights to |
Genentech also acquired nonexclusive, worldwide rights to diagnostic and small- molecule products for human use based on the same gene; HGS will receive an up-front fee and annual maintenance fees, and is entitled to development milestones and royalties (8/7) |
|
|
||
ILEX Oncology Inc. (ILXO) |
Ventana |
License and development agreement to exclusively sublicense to Ventana |
Further details were not disclosed (8/1) |
|
|
||
Inpharmatica Ltd.* (UK) |
Ionix Pharmaceuticals Ltd.* (UK) |
Nonexclusive ADME service agreement |
The companies will work to generate in vitro and pharmacokinetic ADME data for certain Ionix product development programs (8/7) |
|
|
|
|
Latitude Pharmaceuticals Inc.* |
Patent |
Exclusive rights agreement to a drug delivery technology from Latitude called advanced drug delivery emulsion |
The technology is designed to reduce problems associated with intravenous administration of numerous macrolide drugs, including clarithromycin and other broad-spectrum antimicrobials (8/13) |
|
|
|
|
LION |
Norak |
Agreement in which Norak acquired the ChemFolio library |
Norak will screen the library against its own G protein-coupled receptors of interest in combination with Transfluor bio-assay and automated high-throughput screening instru-ments to search for synthetic compounds (8/5) |
|
|
|
|
MaxCyte |
Cognate Therapeutics |
Agreement to develop multiple nonviral, gene-based cancer products using a cell-loading system belonging to MaxCyte |
MaxCyte will receive an undisclosed up-front payment and milestone, research and development funding, as well as royalties from sales (7/16) |
|
|
||
Millennium Pharmaceuticals Inc. (MLNM) |
Ortho Biotech Products LP (unit |
Agreement in which Ortho will help develop Velcade and will market it overseas |
Ortho will pay as much as $500M in development costs, and will later commercialize it outside the U.S. and pay Millennium royalties; Millennium retains U.S. rights (7/1) |
|
|
|
|
NeoGenesis Pharmaceuticals Inc.* |
Amgen Inc. |
Multiyear collaboration to discover small-molecule drugs for cancer and neurodegenerative and inflammatory diseases |
NeoGenesis will use its drug discovery technologies, including its Automated Ligand Identification System platform, NeoMorph compound libraries and lead optimization technologies, to discover candidates against selected targets; NeoGenesis will receive research funding and milestone and royalty payments (8/4) |
|
|
|
|
Neurome Inc.* |
La Jolla Pharmaceutical Co. (LJPC) |
Collaboration to focus on proteins in the brain that selectively bind antibodies to double-stranded DNA found in patients with systemic lupus erythematosus |
The collaboration combined Neurome's technologies with La Jolla's experience in discovering and developing therapeutics to treat the underlying causes of antibody-mediated diseases (7/9) |
|
|
||
Nutraceutical Development Corp. (subsidiary of Endovasc Inc.; OTC BB:EVSC) |
Basic Research* |
Product licensing agreement in which Basic Research will invest at least $2.5M in developing, commercializing and marketing Endovasc's Muscle Mass Technology for nutraceutical products |
Basic Research also will pay Endovasc a 10% royalty on all revenues generated by the nutraceutical products with a benchmark of $2M minimum royalty beginning in the second year (7/9) |
|
|||
Point Technologies Inc.* |
Incyte Corp. (INCY) |
Agreement under which Point Tech sublicensed U.S. Patent Nos. 5,807,522 and 6,110,426, which are directed to a method of making a nucleic acid array by tapping the tip of a dispensing device against a solid support |
The agreement grants a worldwide, non-exclusive, nontransferable license under the patents, to make and sell split micro-array spotting pins (6/24) |
|
|
|
|
Prima Biomed Ltd. (Australia; ASX:PRR) |
Prana Biotechnology Ltd. (Australia; PRAN; SX:PBT) |
Collaboration to develop an Alzheimer's disease vaccine |
Prima will work with Prana as well as the Austin Research Institute and the University of Melbourne; Prima will apply its PanVax vaccine technology, Dctag, to metal protein-attenuating compounds developed by Prana (8/8) |
|
|
|
|
Prolume Ltd.* |
Genome BioSciences Inc.* |
Nonexclusive technology sublicensing agreement for the use and marketing of Renilla green fluorescent protein technologies |
Genome BioSciences may use the technologies in the application of its Positive-Positive Selection gene targeting method- ologies for the creation of genetically engineered cell lines and mice (8/13) |
|
|
||
Provid Pharmaceuticals Inc.* |
BTG (unit of BTG plc; UK; LSE:BGC) |
Collaboration to develop small-molecule drug candidates for a project in inflammatory diseases |
The project is part of the BTG technology portfolio in the life sciences and resulted from an academic discovery licensed to BTG for development and commercialization (7/10) |
|
|
|
|
Rosetta Biosoftware |
Mendel Biotechnology Inc.* |
Licensing agreement for the Rosetta Resolver system |
Mendel licensed the system; further details were not disclosed (7/1) |
|
|
|
|
SciTegic Inc.* |
Chiron |
Licensing agreement giving Chiron access to Pipeline Pilot, a software product designed to help with compound library acquisition and activity modeling for optimizing |
Chiron acquired the technology for multiple internal users, as well as a license for its web interface that allows additional users to access and execute data processing protocols remotely (7/28) |
|
|
|
|
SurroMed |
MediBic* |
Agreement in which the companies will collaborate on the development of biomarker discovery product offerings |
MediBic will act as SurroMed's exclusive sales representative in Japan for SurroMed's biomarker discovery solutions (7/31) |
|
|||
Tripos |
ChanTest |
Collaboration to develop a model that predicts which drug compounds are likely to produce cardiac liability due to blockage of the hERG ion channel |
Tripos will select and provide compounds for testing by ChanTest, from which Tripos will develop the predictive model and employ it to examine clients' data resulting from ChanTest's analysis of lead candidates (6/26) |
|
|
|
|
Viventia |
Affitech A/S* (Norway) |
Research collaboration to identify antigens on various cancer cells and to select antibodies targeting those antigens for subsequent development as potential therapeutics |
Affitech will employ its human antibody libraries and its discovery and screening technologies to cancer cells in order to simultaneously discover cell surface targets and their respective antibodies; Viventia will apply its ImmunoMine screening and Unlock target identification platforms to further characterize and validate those antigens and antibodies (6/23) |
|
|
||
XOMA Ireland Ltd. (division of XOMA Ltd.; XOMA) |
Xerion Pharmaceuticals AG* (Germany) |
License agreement in which Xerion receives rights to use the XOMA antibody expression technology for developing antibody products derived from phage display libraries for itself and Xerion collaborators |
Xerion also has an option to license the production of antibodies under the XOMA patents; XOMA will receive license and royalty payments from Xerion; Xerion and XOMA have a co-development and commercialization option on antibody products generated by Xerion (8/13) |
|
|||
| | |||
Notes: | |||
# This chart does not include agreements that involve agricultural product development. | |||
* Private companies are indicated with an asterisk. | |||
** Denotes the date the item ran in BioWorld International. | |||
Unless otherwise noted, the trading symbols listed for public biotechnology companies are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
